At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
ELX-02drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02
In Brief
A Phase 1 clinical trial evaluating ELX-02 for Impaired Renal Function. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
Phase 1 - Pharmacokinetics in Patients with Impaired Renal Function
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImpaired Renal Function
CountriesUnited States
CollaboratorsSyneos Health
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartJan 2019
Primary CompletionJul 2019
Study CompletionAug 2019
TodayJul 2026
First PostedDec 14, 2018
Enrollment StartJan 4, 2019
Primary CompletionJul 30, 2019
Study CompletionAug 7, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.5 years ago
Interventions
ELX-02drug
ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.